MA37672A1 - Formulation d'agoniste des récepteurs à la somatostatine - Google Patents

Formulation d'agoniste des récepteurs à la somatostatine

Info

Publication number
MA37672A1
MA37672A1 MA37672A MA37672A MA37672A1 MA 37672 A1 MA37672 A1 MA 37672A1 MA 37672 A MA37672 A MA 37672A MA 37672 A MA37672 A MA 37672A MA 37672 A1 MA37672 A1 MA 37672A1
Authority
MA
Morocco
Prior art keywords
weight
forming
somatostatin receptor
compositions
receptor agonist
Prior art date
Application number
MA37672A
Other languages
English (en)
Inventor
Catalin Nistor
Markus Johnsson
Fredrik Tiberg
Original Assignee
Camurus Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49623188&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA37672(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/EP2012/059917 external-priority patent/WO2012160213A1/fr
Application filed by Camurus Ab filed Critical Camurus Ab
Publication of MA37672A1 publication Critical patent/MA37672A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases or cochleates; Sponge phases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Dispersion Chemistry (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention porte sur des compositions formant un mélange de faible viscosité de : a) 20-50 % en poids d'au moins un diacylglycérol ; b) 20-54 % en poids d'au moins une phosphatidylcholine (pc) ; c) 5-15 % en poids d'au moins un solvant monoalcoolique organique biocompatible ; d) 1 à 20 % en poids d'un solvant polaire ; e) 5 à 150 mg/ml d'au moins un agoniste peptidique des récepteurs à la somatostatine comprenant du pasireotide ; f) éventuellement au moins un antioxydant ; le rapport des composants a:b étant dans la plage de 40:60 à 54:46 ; la préformulation formant, ou pouvant former, au moins une structure de phase à cristaux liquides au contact avec un fluide aqueux en excès. L'invention porte en outre sur des procédés de traitement comprenant l'administration de telles compositions et sur des dispositifs d'administration préremplis et des trousses contenant les formulations.
MA37672A 2012-05-25 2013-05-24 Formulation d'agoniste des récepteurs à la somatostatine MA37672A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/EP2012/059917 WO2012160213A1 (fr) 2011-05-25 2012-05-25 Formulations peptidiques à libération contrôlée
US201261730613P 2012-11-28 2012-11-28
PCT/EP2013/060739 WO2013174978A1 (fr) 2012-05-25 2013-05-24 Formulation d'agoniste des récepteurs à la somatostatine

Publications (1)

Publication Number Publication Date
MA37672A1 true MA37672A1 (fr) 2016-07-29

Family

ID=49623188

Family Applications (1)

Application Number Title Priority Date Filing Date
MA37672A MA37672A1 (fr) 2012-05-25 2013-05-24 Formulation d'agoniste des récepteurs à la somatostatine

Country Status (23)

Country Link
US (3) US11672843B2 (fr)
JP (1) JP6374380B2 (fr)
KR (1) KR102139080B1 (fr)
CN (1) CN104487050B (fr)
AU (1) AU2013265210B2 (fr)
BR (1) BR112014029425A2 (fr)
CA (1) CA2874367C (fr)
CL (1) CL2014003185A1 (fr)
CO (1) CO7160067A2 (fr)
DK (1) DK2861209T3 (fr)
EA (1) EA035495B1 (fr)
ES (1) ES2834318T3 (fr)
HK (1) HK1207985A1 (fr)
IL (1) IL235740A0 (fr)
IN (1) IN2014DN09831A (fr)
MA (1) MA37672A1 (fr)
MX (1) MX350964B (fr)
NZ (1) NZ702028A (fr)
PE (1) PE20150195A1 (fr)
PH (1) PH12014502614A1 (fr)
SG (1) SG11201407678YA (fr)
TN (1) TN2014000483A1 (fr)
WO (1) WO2013174978A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8236292B2 (en) * 2004-06-04 2012-08-07 Camurus Ab Liquid depot formulations
CN103702662B (zh) * 2011-05-25 2018-07-20 卡穆鲁斯公司 控制释放肽制剂
MX383392B (es) 2016-09-27 2025-03-13 Camurus Ab Mezclas y formulaciones que comprenden una sal de alquil amonio de ácido etilendiaminotetraacético (edta).
CN113018248B (zh) * 2019-12-23 2022-07-22 南京清普生物科技有限公司 一种缓释递药系统
CN114240934B (zh) * 2022-02-21 2022-05-10 深圳大学 一种基于肢端肥大症的图像数据分析方法及系统

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2209937B (en) 1987-09-21 1991-07-03 Depiopharm S A Water insoluble polypeptides
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5340802A (en) 1989-06-30 1994-08-23 Abbott Laboratories Peptide analog type-B CCK receptor ligands
PH30995A (en) 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
CA2535463A1 (fr) 1989-07-07 1991-01-08 Novartis Ag Octreotide-pamoate et son utilisation dans des formulations de peptides hydrosolubles a liberation prolongee
MY107937A (en) 1990-02-13 1996-06-29 Takeda Chemical Industries Ltd Prolonged release microcapsules.
BR9206593A (pt) 1991-10-04 1995-11-28 Gs Biochem Ab Partículas especialmente partículas coloidais processo de prepará-las a partir de uma fase cristalina líquida homogênea ou fase L3 composição farmacêutica e uso destas partículas
WO1993006921A1 (fr) 1991-10-04 1993-04-15 Gs Biochem Ab Particules, procede de preparation desdites particules et utilisations
US6228383B1 (en) 1994-03-03 2001-05-08 Gs Development Ab Use of fatty acid esters as bioadhesive substances
ATE180971T1 (de) 1994-03-30 1999-06-15 Gs Dev Ab Verwendung von fettsäureester als bioklebstoffe
SE518578C2 (sv) 1994-06-15 2002-10-29 Gs Dev Ab Lipidbaserad komposition
FR2725369B1 (fr) 1994-10-07 1997-01-03 Oreal Composition cosmetique ou dermatologique constituee d'une emulsion huile dans eau a base de globules huileux pourvus d'un enrobage cristal liquide lamellaire
JPH11513393A (ja) 1995-10-12 1999-11-16 ジーエス ディベロップメント エービー 皮膚又は粘膜表面へのもしくは介する活性物質の投与用医薬組成物
US6458924B2 (en) 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
PT839525E (pt) 1996-10-31 2004-10-29 Takeda Chemical Industries Ltd Preparacao de libertacao prolongada
AU6919598A (en) 1997-04-17 1998-11-13 Dumex-Alpharma A/S A novel bioadhesive drug delivery system based on liquid crystals
US6638621B2 (en) 2000-08-16 2003-10-28 Lyotropic Therapeutics, Inc. Coated particles, methods of making and using
US20040018241A1 (en) 1997-09-26 2004-01-29 Noven Pharmaceuticals, Inc. Bioadhesive compositions and methods for topical administration of active agents
US6320017B1 (en) 1997-12-23 2001-11-20 Inex Pharmaceuticals Corp. Polyamide oligomers
BE1011899A6 (fr) 1998-04-30 2000-02-01 Ucb Sa Compositions pharmaceutiques gelifiables utilisables.
SI1140148T1 (sl) 1998-12-22 2006-04-30 Lilly Co Eli Stabilna formulacija raztopine glukagonu podobnega peptida-1
US6011067A (en) 1999-06-11 2000-01-04 Thione International, Inc. Antioxidant composition for the treatment of psoriasis and related diseases
GB0018891D0 (en) * 2000-08-01 2000-09-20 Novartis Ag Organic compounds
US20020153508A1 (en) 2000-06-29 2002-10-24 Lynch Matthew Lawrence Cubic liquid crystalline compositions and methods for their preparation
US7008646B2 (en) 2001-02-20 2006-03-07 Patrick Thomas Spicer Cubic liquid crystalline compositions and methods for their preparation
US6656385B2 (en) 2001-02-21 2003-12-02 The Procter & Gamble Company Functionalized cubic liquid crystalline phase materials and methods for their preparation and use
US6936187B2 (en) 2001-02-21 2005-08-30 Matthew Lawrence Lynch Functionalized cubic liquid crystalline phase materials and methods for their preparation and use
US6991809B2 (en) 2001-06-23 2006-01-31 Lyotropic Therapeutics, Inc. Particles with improved solubilization capacity
WO2003002136A2 (fr) 2001-06-28 2003-01-09 Novo Nordisk A/S Formulation stable de glp-1 modifie
EP1474163A2 (fr) 2002-01-10 2004-11-10 Imperial College Innovations Limited Modification des habitudes alimentaires
US7622118B2 (en) 2002-07-15 2009-11-24 Board Of Regents, The University Of Texas System Cancer treatment methods using selected antibodies to aminophospholipids
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
GB0305941D0 (en) 2003-03-14 2003-04-23 Camurus Ab Composition
GB0307777D0 (en) 2003-04-04 2003-05-07 Medical Res Council Conjugate compounds
WO2005014162A1 (fr) 2003-08-04 2005-02-17 Camurus Ab Procede d'amelioration des proprietes de particules amphiphiles
WO2005021022A2 (fr) 2003-09-01 2005-03-10 Novo Nordisk A/S Formulations de peptides stables
GB0322033D0 (en) 2003-09-19 2003-10-22 Camurus Ab Composition
PL1682091T3 (pl) 2003-11-07 2017-09-29 Camurus Ab Kompozycje lipidów i kationowych peptydów
WO2006075124A1 (fr) * 2005-01-14 2006-07-20 Camurus Ab Formulations à base d'analogues de somatostatine
WO2005063213A1 (fr) 2003-12-19 2005-07-14 Biodelivery Sciences International, Inc. Compositions cochleaires liposomales rigides et leurs procedes de fabrication
ATE489942T1 (de) 2004-01-23 2010-12-15 Camurus Ab Ternäre nichtlamellare lipidzusammensetzungen
GB0401513D0 (en) 2004-01-23 2004-02-25 Camurus Ab Compositions
US8236292B2 (en) * 2004-06-04 2012-08-07 Camurus Ab Liquid depot formulations
PL1778187T3 (pl) 2004-08-04 2012-09-28 Camurus Ab Kompozycje tworzące nielamelarne dyspersje
PL1848403T3 (pl) 2005-01-14 2010-09-30 Camurus Ab Preparaty bioadhezyjne o działaniu miejscowym
US9757461B2 (en) * 2005-01-14 2017-09-12 Camurus Ab GnRH analogue formulations
EP1843746B1 (fr) * 2005-01-14 2011-03-16 Camurus Ab Formulations à base d'analogues de somatostatine
KR101245022B1 (ko) * 2005-01-21 2013-03-19 카무러스 에이비 약제학적 지질 조성물
US8097239B2 (en) 2005-06-06 2012-01-17 Camurus Ab Controlled-release formulations
EP1888031B1 (fr) * 2005-06-06 2013-01-23 Camurus Ab Formulations d'analogues de glp-1
CN103071209A (zh) 2005-11-17 2013-05-01 周吉尼克斯股份有限公司 用无针注射递送粘稠制剂
GB0602639D0 (en) * 2006-02-09 2006-03-22 Novartis Ag Organic compounds
PE20090387A1 (es) * 2007-05-24 2009-04-28 Novartis Ag Formulacion de pasireotida
GB0711656D0 (en) 2007-06-15 2007-07-25 Camurus Ab Formulations
GB0716385D0 (en) 2007-08-22 2007-10-03 Camurus Ab Formulations
WO2010003939A1 (fr) 2008-07-08 2010-01-14 Novartis Ag Utilisation de pasiréotide pour le traitement d'une hypoglycémie hyperinsulinémique endogène
GB0815435D0 (en) 2008-08-22 2008-10-01 Camurus Ab Formulations
CN103702662B (zh) * 2011-05-25 2018-07-20 卡穆鲁斯公司 控制释放肽制剂
MX350929B (es) * 2011-12-05 2017-09-26 Camurus Ab Formulaciones peptidicas robustas de liberación controlada.

Also Published As

Publication number Publication date
PE20150195A1 (es) 2015-02-27
IL235740A0 (en) 2015-01-29
CN104487050B (zh) 2019-08-20
CN104487050A (zh) 2015-04-01
CO7160067A2 (es) 2015-01-15
US20230372436A1 (en) 2023-11-23
JP6374380B2 (ja) 2018-08-15
AU2013265210A1 (en) 2014-12-04
EA201491928A1 (ru) 2015-09-30
BR112014029425A2 (pt) 2017-06-27
KR102139080B1 (ko) 2020-07-29
US20150105332A1 (en) 2015-04-16
NZ702028A (en) 2016-07-29
ES2834318T3 (es) 2021-06-17
KR20150016977A (ko) 2015-02-13
MX350964B (es) 2017-09-27
CA2874367C (fr) 2020-08-18
CA2874367A1 (fr) 2013-11-28
US20260000730A1 (en) 2026-01-01
WO2013174978A1 (fr) 2013-11-28
US11672843B2 (en) 2023-06-13
PH12014502614A1 (en) 2015-01-21
TN2014000483A1 (en) 2016-03-30
JP2015520762A (ja) 2015-07-23
IN2014DN09831A (fr) 2015-08-07
HK1207985A1 (en) 2016-02-19
AU2013265210B2 (en) 2016-09-15
SG11201407678YA (en) 2014-12-30
MX2014014379A (es) 2015-02-05
EA035495B1 (ru) 2020-06-25
CL2014003185A1 (es) 2015-04-24
DK2861209T3 (da) 2020-12-21

Similar Documents

Publication Publication Date Title
MA37672A1 (fr) Formulation d'agoniste des récepteurs à la somatostatine
AR060784A1 (es) Mezclas binarias de acido hialuronico y su uso terapeutico
AR071959A1 (es) Derivado de benceno o tiofeno y su uso como inhibidor de vap-1
BR112014032695A2 (pt) formulações estáveis para injeção parenteral de fármacos de pequenas moléculas
EA201291108A1 (ru) Фармацевтические композиции в виде эмульсии с низким содержанием масла, содержащие прогестоген
MA38698A1 (fr) Système d'administration transdermique
SV2005002044A (es) Solidos supersaturados estabilizados de drogas lipofilicas ref. p-sv-77.892/gh
FR3067930B1 (fr) Dispersions comprenant au moins une huile volatile hydrocarbonee
EA201491005A1 (ru) Устойчивые составы с контролируемым высвобождением
AR089673A1 (es) Formulacion de premezcla de dexmedetomidina
MA35136B1 (fr) Formulation pour un anticorps anti-a4b7
EA201491685A1 (ru) Препарат для инъекций
AR033221A1 (es) Composicion farmaceutica finamente autoemulsionable
BR112012023455A2 (pt) composição de material, preparação e uso da mesma
FR2999924B1 (fr) Association d'actifs comprenant au moins une huile essentielle, une cyclodextrine et un corps gras liquide et composition la contenant.
CO6602159A2 (es) Formulaciones de aceite que comprenden compuestos de ciclopropeno
BRPI0506812A (pt) composição base auto-microemulsificável, microemulsão e método de preparação da composição base auto-microemulsificável
PE20171622A1 (es) Formulacion de relacion fija de insulina glargina/lixisenatida
ATE507818T1 (de) Orale verabreichung eines calcitonins
MX2021003766A (es) Formulaciones de anticuerpos anti-fgfr2.
CY1109430T1 (el) Υγρη συνθεση περιλαμβανουσα αργινινη και α-λιποϊκο οξυ και χρηση αυτης για βελτιωση της σεξουαλικης λειτουργιας
Evans et al. Binding of local anaesthetics to the lipid emulsion Clinoleic™ 20%
ATE489100T1 (de) Gleitmittelzubereitung
CA3037593A1 (fr) Composition pharmaceutique comprenant des cetones polyinsaturees a longue chaine dans un vehicule de silicone
ATE450241T1 (de) Dünnflüssige w/o emulsionen